Business
Sandra M. Swain, MD, FACP, FASCO Joins Jaguar Health's Scientific Advisory Board
SAN FRANCISCO, CA / ACCESSWIRE / January 11, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) and its wholly owned subsidiary Napo Pharmaceuticals (Napo) today
About this update from Jaguar Health, Inc.
[{"type":"text","content":"SAN FRANCISCO, CA / ACCESSWIRE / January 11, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) and its wholly owned subsidiary Napo Pharmaceuticals (Napo) today announced that Sandra M. Swain, MD, FACP, FASCO has joined the Jaguar/Napo Scientific Advisory Board (SAB).\"We are thrilled that Dr. Swain has joined our SAB,\" said Pravin Chaturvedi, PhD, Napo and Jaguar's Chair of the Scientific Advisory Board and Chief Scientific Officer. \"She is an internationally renowned physician/scientist and has more than 30 years of experience in clinical trial design, implementation and execution of major international clinical trials, including and especially breast cancer. She brings a critical perspective that will augment our clinical development program focused on addressing the high unmet need of cancer therapy-related diarrhea (CTD). Her participation will buttress our efforts to mitigate the unrecognized burden of diarrhea in cancer patients. She has been a pioneer in addressing the gastrointestinal toxicities of cancer therapies, as evidenced by her design and execution of the HALT-D trial, a first prophylactic study of crofelemer in HER2-positive breast cancer patients receiving targeted therapies with standard chemotherapy. The results from the HALT-D trial were published last year. Her recognition of the burden of CTD on patients as well as the need for prophylaxis of CTD provide further support to our ongoing OnTarget phase 3 trial. We welcome Dr. Swain to our SAB and her input and advice will augment our continued pioneering efforts to address CTD.\"Lisa Conte, Jaguar's founder, president and CEO added, \"Dr. Swain's focus on patient comfort and dignity is admirable and has a direct benefit on the outcome of the treatment of cancer. The patient community benefits from her vision and leadership.\"Dr. Swain is the Associate Dean for Research Development and Professor of Medicine at the Georgetown University Medical Center (GUMC) and the Vice President of Genetic Medicine for MedStar Health in Washington, DC. Previously she held leadership roles at the National Cancer Institute (NCI), National Institutes of Health (NIH) and the Washington Cancer Institute at MedStar Washington Hospital Center. She has served on the Board of Directors for the American Society of Clinical Oncology (ASCO) and is a past President of ASCO (2012-2013. Dr. Swain...